Basilea Pharmaceutica - Third oncology asset sale announced, as planned
Basilea announced another successful oncology asset sale as a part of its strategic plan to focus on its core anti-infectives business. The company is anticipated to receive up to CHF3.0m in upfront and near-term milestones for its novel preclinical inhibitors of CLK kinases from Twentyeight-Seven (28-7) Therapeutics, a privately held US biotech. The deal will see Basilea with potential future development, regulatory and sales milestones payments of up to CHF351m. This is the third oncology sale in H222, and we view this latest development as a positive indicator for management realising its aim for the separation of its oncology business by end-FY22. We maintain our valuation of Basilea at CHF903.5m or CHF76.3/share.Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.